President, Cofounder
CurrentPOP Biotechnologies (POP BIO): POP BIO is a privately held clinical stage biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies.POP BIO has generated over $16M in capital for the development of their proprietary technologies through a combination of equity investment, federal grants, and research collaborations.POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development, validation, and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against a wide range of targets including infectious disease, cancer, and chronic disease through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle-formation and liposome display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.